Publication | Closed Access

Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer

Liposomal CisplatinMedicinePathologyPhase Ii StudyAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyLung CancerFirst Line Treatment